Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition

Immunotherapy for ovarian cancer is an area of intense investigation since the majority of women with relapsed disease develop resistance to conventional cytotoxic therapy. The paucity of safe and validated target antigens has limited the development of clinically relevant antibody-based immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeku, Oladapo O., Rao, Thapi Dharma, Laster, Ian, Kononenko, Artem, Purdon, Terence J., Wang, Pei, Cui, Ziyou, Liu, Hong, Brentjens, Renier J., Spriggs, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079980/
https://www.ncbi.nlm.nih.gov/pubmed/33936101
http://dx.doi.org/10.3389/fimmu.2021.663379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079980/
https://www.ncbi.nlm.nih.gov/pubmed/33936101
http://dx.doi.org/10.3389/fimmu.2021.663379

Ejemplares similares